Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada.
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Turin, Italy.
Clin Genitourin Cancer. 2019 Oct;17(5):395-401. doi: 10.1016/j.clgc.2019.07.008. Epub 2019 Jul 19.
We examined the changes over time in other-cause mortality (OCM) rates in patients with clinically localized prostate cancer (PCa) as an indicator of patient selection.
Within the Surveillance, Epidemiology, and End Results database (1987-2011), we identified patients with PCa treated with either radical prostatectomy (RP) (n = 230,969; 62.8%) or external beam radiation therapy (EBRT) (n = 136,915; 37.2%). Temporal trends and multivariable Cox regression analyses assessed OCM at 5 years using stratification according to year of diagnosis (1987-1991 vs. 1992-1996 vs. 1997-2001 vs. 2002-2006 vs. 2007-2011), age group, and ethnicity.
In patients who had undergone RP, the OCM rates at 5 years of follow-up decreased over time from 7.9% to 2.4% (slope, -0.25%/year) versus from 15.2% to 9.9% after EBRT (slope, -0.29%/year). The greatest decrease in 5-year OCM rates over time was recorded in patients ≥ 75 years (16.0%-12.0%; slope, -0.25%/year), followed by younger age categories (70-74 years, -0.21%/year; 65-69 years, -0.17%/year; 60-64 years, -0.10%/year; < 60 years, -0.07%/year), as well as in African-American men (11.0%-5.1%; slope, -0.32%/year), followed by Caucasian (7.6%-3.4%; slope, -0.21%/year) and Hispanic men (7.0%-3.1%; slope, -0.20%/year; all P < .001), as corroborated in multivariable Cox regression models.
OCM rates were highest in oldest individuals and in African-American men. In both groups, an important 5-year OCM reduction over the 25-year study span was recorded. Nonetheless, these 2 patient groups may still represent the ideal target for better patient selection based on OCM considerations, because their most recent OCM rates exceeded those of, respectively, younger and Caucasian patients.
我们研究了临床局限性前列腺癌(PCa)患者其他原因死亡率(OCM)随时间的变化,以此作为患者选择的指标。
在监测、流行病学和最终结果数据库(1987-2011 年)中,我们确定了接受根治性前列腺切除术(RP)(n=230969;62.8%)或外照射放疗(EBRT)(n=136915;37.2%)治疗的 PCa 患者。使用按诊断年份(1987-1991 年 vs. 1992-1996 年 vs. 1997-2001 年 vs. 2002-2006 年 vs. 2007-2011 年)、年龄组和种族分层的方法,对 5 年 OCM 率进行了时间趋势和多变量 Cox 回归分析。
在接受 RP 的患者中,5 年随访的 OCM 率随时间从 7.9%降至 2.4%(斜率,-0.25%/年),而 EBRT 后从 15.2%降至 9.9%(斜率,-0.29%/年)。5 年 OCM 率随时间下降最大的是≥75 岁的患者(16.0%-12.0%;斜率,-0.25%/年),其次是年轻患者(70-74 岁,-0.21%/年;65-69 岁,-0.17%/年;60-64 岁,-0.10%/年;<60 岁,-0.07%/年)和非裔美国人(11.0%-5.1%;斜率,-0.32%/年),其次是白种人(7.6%-3.4%;斜率,-0.21%/年)和西班牙裔(7.0%-3.1%;斜率,-0.20%/年;均 P<0.001),多变量 Cox 回归模型也证实了这一点。
OCM 率在最年长的个体和非裔美国人中最高。在这两个群体中,在 25 年的研究期间,OCM 都有显著降低。尽管如此,由于最近的 OCM 率超过了年轻和白种患者,这两个患者群体可能仍然是基于 OCM 考虑进行更好的患者选择的理想目标。